A rodent model of schizophrenia reveals increase in creatine kinase activity with associated behavior changes

Oxidative Medicine and Cellular Longevity

Volumn 3, Issue 6, 2010, Pages 421-427

  Canever, Leila ^a   Oliveira, Larissa ^a   De Luca, Renata D'Altoé ^a   Correa, Paulo T F ^a   Fraga, Daiane De B ^a   Matos, Maria Paula ^a   Scaini, Giselli ^a   Quevedo, João ^a   Streck, Emílio L ^a   Zugno, Alexandra I ^a  

^a UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

Author keywords

Behavioral; Brain; Creatine kinase; Energy metabolism; Ketamine; Schizophrenia

Indexed keywords

AMINES; ANESTHETICS; DISEASES; ENZYMES; METABOLISM; RATS; TOPOGRAPHY;

BEHAVIORAL; CREATINE KINASE; ENERGY METABOLISM; KETAMINE; SCHIZOPHRENIA;

BRAIN;

CREATINE KINASE; KETAMINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR CHANGE; BRAIN METABOLISM; BRAIN REGION; CONTROLLED STUDY; DRUG DOSE COMPARISON; ENERGY METABOLISM; ENZYME ACTIVITY; HABITUATION; HYPERACTIVITY; MALE; NONHUMAN; PATHOGENESIS; RAT; SCHIZOPHRENIA; SOCIAL INTERACTION; STEREOTYPY; ANIMAL; BRAIN; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG EFFECT; ENZYMOLOGY; METABOLISM; MOTOR ACTIVITY; PATHOPHYSIOLOGY; PSYCHOLOGY; WISTAR RAT;

ANIMALIA; RATTUS; RODENTIA;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CREATINE KINASE; DISEASE MODELS, ANIMAL; KETAMINE; MALE; MOTOR ACTIVITY; RATS; RATS, WISTAR; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 79951541496     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.4161/oxim.3.6.13446     Document Type: Article

References (63)

1. Stefan M, Travis M, Murray R. An atlas of schizophrenia. (The encyclopedia of visual medicine series), Part Publisc G London UK 2002.
2. Robertson GS, Hori SE, Powell KJ. Schizophrenia: an integrative approach to modelling a complex disorder. J Psychiatric Neurosci 2006; 31:157-67. (Pubitemid 43954734)
3. Bowie CR, Harvey PD. Schizophrenia from a Neuropsychiatric Perspective. Mt Sinai J Med 2006; 73:993-8. (Pubitemid 46040397)
4. Geyer MA, Moghaddam B. Animal models relevant to schizophrenia disorders. Neuropsychopharmacology: The Fifth Generation of Progress. In: Davis KL, Dennis Charney D, Coyle JT, Nemeroff C. Am Coll Neuropsychopharmacol USA 2002.
5. Van den Buuse M, Garner B, Gogos A, Kusljic S. Importance of animal models in schizophrenia. Res Aust N Z J Psychiatric 2005; 39:550-7.
6. Trujillo KA, Zamora JJ, Warmoth KP. Increased responde to ketamine follwing treatment at long intervals: implications for intermittent use. Biol Psychiatry 2008; 63:178-83. (Pubitemid 350299316)
7. Becker A, Grecksch G. Ketamine-induced changes in rat behavior: a possibl animal model of schizophrenia. Test of predictive validity. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28:1267-77. (Pubitemid 39592924)
8. Becker A, Peters B, Schroeder H, Mann T, Huether G, Grecksch G. Ketamine-induced changes in rat behaviour: A possible animal model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatric 2003; 27:687-700. (Pubitemid 36645072)
9. Ellison G. The N-methyl-d-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias. Brain Res Bull 1995; 20:250-67.
10. Mattson MP, Gleichmann M, Cheng A. Mitochondria in neuroplasticity and neurobiological disorders. Neuron 2008; 60:748-66.
11. Goto Y. Mitochondrial dysfunction and brain development disorders. No To Shinkei 2001; 53:421-6. (Pubitemid 32530218)
12. Prince JA, Yassin MS, Oreland L. Neuroleptic-induced mitochondrial enzyme alterations in the rat brain. J Pharmacol Exp Ther 1997; 280:261-7. (Pubitemid 27171411)
13. Manfredi G, Beal MF. The role of mitochodrial in the pathogenesis of neurodegenerative diseases. Brain Pathol 2000; 10:462-72. (Pubitemid 30431299)
14. Kung L, Roberts RC. Mitochondrial pathology in human schizophrenic striatum: a postmortem ultrastructural study. Synapse 1999; 31:67-75. (Pubitemid 29009281)
15. Pieczenick SR, Neustadt J. Mitochondrial dysfunction and molecular pathways of disease. Exp Mol Pathol 2007; 83:84-92. (Pubitemid 46842959)
16. Wallimann T, Wyss M, Brdiczka D, Nicolay K, Eppenberger HM. Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the phosphocreatine circuit' for cellular energy homeostasis. Biochem J 1992; 281:21-40.
17. Pilla C, Cardozo RFO, Dornelles PKB, Dutra-Filho CS, Wyse T, Angela TS, et al. Kinetic studies on the inhibition of creatine kinase activity by branched-chain α-amino acids in the brain cortex of rats. I J Develop Neurosci 2003; 21:145-51. (Pubitemid 36444539)
18. Ben-Schachar D. The interplay between mitochondrial complex I, dopamine and Sp1 in schizophrenia. J Neural Transm 2009; 116:1383-96.
19. Karry R, Klein E, Ben-Shachar D. Mitochondrial complex I subunits expression is altered in schizophrenia: a postmortem study. Biol. Psychiatry 2004; 55:676-84. (Pubitemid 38376178)
20. Schlattner U, Forstner M, Eder M, Stachowiak O, Fritz-Wolf K, Wallimann T. Functional aspects of the X-ray structure of mitochondrial creatine kinase: a molecular physiology approach. Mol Cell Biochem 1998; 184:125-40. (Pubitemid 28398605)
21. Aksenov M, Aksenova MV, Payne RM, Trojanovski JQ, Schmidt KL, Carney JM, et al. Oxidation of cytosolic proteins and expression of creatine kinase BB in frontal lobes of neurodegenerative disorders. Dement Geriatr Cogn Disord 1999; 10:158-65. (Pubitemid 29099701)
22. Freitas TP, Scaini G, Côrrea C, Santos PM, Ferreira GK, Rezin GT, et al. Evaluation of brain creatine kinase activity in an animal model of mania induced by ouabain. J Neural Transm 2010; 117:149-53.
23. Lewis DA, Lieberman JA. Catching up on schizophrenia: natural history and neurobiology. Neuron 2000; 28:325-34.
24. Covington MA, Riedel WJ, Brown B, He C, Morris E, Weinstein S, et al. Does ketamine mimic aspects of schizophrenic speech? J Psychopharmacol 2007; 21:338-46.
25. Garcia LS, Comim CM, Valvassori SS, Réus GZ, Andreazza AC, Stertz L, et al. Chronic administration of ketamine elicits antidepressant-like effects in rats without affecting hippocampal brain-derived neurotrophic factor protein levels. Basic Clin Pharmacol Toxicol 2008; 103:502-6.
26. Rezin GT, Gonçalves CL, Daufenbach JF, Fraga DB, Santos PM, Ferreira GK, et al. Acute administration o ketamine reverses the inhibition of mitochondrial respiratory chain induced by chronic mild stress 2009; 79:418-21.
27. Littlewood CL, Jones N, O'Neill MJ, Mitchell SN, Tricklebank M, Williams SC. Mapping the central effects of ketamine in the rat using pharmacological MRI. Psychopharmacol 2006; 188:261-72.
28. Hunt MJ, Raynaud B, Garcia R. Ketamine dosedependently unduces high-frequency oscillations in the nucleus accumbens in freely moving rats. Biol Psychiat 2006; 60:1206-14. (Pubitemid 44693529)
29. Jang HS, Choi HS, Lee SH, Jang KH, Lee MG. Evaluation of the anaesthetic effects of medetomidine and ketamine in rats and their reversal with atipamezole. Vet Anaesth Analg 2009; 36:319-27.
30. Pfenninger E, Himmelseher S. Neuroprotection by ketamine at the cellular level. Anaesthesist 1997; 46:47-54.
31. Rudin M, Ben-Abraham R, Gazit V, Tendler Y, Tashlykov V, Katz Y. Single-dose ketamine administration induces apoptosis in neonatal mouse brain. J Basic Clin Physiol Pharmacol 2005; 16:231-43. (Pubitemid 43089168)
32. Irifune M, Sato T, Kamata Y, Nishikawa T, Nomoto M, Fukuda T, et al. Inhibition by diazepam of ketamine-induced hyperlocomotion and dopamine turnover in mice. Can J Anaesth 1998; 45:471-8. (Pubitemid 28365517)
33. Ridley RM. The psychology of perseverative and stereo-typed behaviour. Prog Neurobiol 1994; 44:221-31.
34. Uranova N, Orlovskaya D, Vikhreva O, Zimina I, Kolomeets N, Vostrikov V, et al. Electron microscopy of oligodendroglia in severe mental illness. Brain Res Bull 2001; 55:597-610. (Pubitemid 32888378)
35. Zipursky RB, Lim KO, Sullivan EV, Brown BW, Pfefferbaum A. Widespread cerebral gray matter volume deficits in schizophrenia 1992; 49:195-205.
36. Toda M, Abi-Dargham A. Dopamine hypothesis of schizophrenia: making sense of it all. Curr Psychiatric Rep 2007; 9:329-36. (Pubitemid 47490006)
37. Tsai G, Coyle TJ. Glutamatergic mechanismos in schizophrenia. Annu Rev Pharmacol Toxicol 2002; 42:165-79.
38. Velligan DL, Bow-Thomas CC. Executive function in schizophrenia. Semin Clin Neuropsychiatry 1999; 4:24-33.
39. Green JF, McElholm A, King DJ. A comparison of the sedative and amnestic effects of chlorpromazine and lorazepam. Psychopharmacol 1996; 128:67-73. (Pubitemid 26379268)
40. Kasai K, Iwanami A, Yamasue H, Kuroki N, Nakagome K, Fukuda M. Neuroanatomy and neurophysiology in schizophrenia. Neurosc Res 2002; 43:93-110. (Pubitemid 34627040)
41. Bertolino A. Dysregulation of dopamine and pathology of prefrontal neurons: neuroimaging studies in schizophrenia and related animal models. Epidemiol Psichiatr Soc 1999; 8:248-54. (Pubitemid 30060649)
42. Oliveira L, Spiazzi CM, Bortolin T, Canever L, Petronilho F, Mina FG, et al. Different sub-anesthetic doses of ketamine increase oxidative stress in the brain of rats. Prog Neuropsychofarmacol Biol Psychiatry 2009; 33:1003-8.
43. Santos IM, Tomé Ada R, Saldanha GB, Ferreira PM, Freitas RM. Oxidative stress in the hippocampus during experimental seizures can be ameliorated with the antioxidant ascorbic acid. Oxid Med Cell Longev 2009; 2:214-21.
44. Bouayed J, Rammal H, Soulomani R. Oxidative stress and anxiety: Relationship and cellular pathways. Oxid Med Cell Longev 2009; 2:63-7.
45. Harrison PJ. The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications. Pychopharmacol 2004; 174:151-62. (Pubitemid 38925100)
46. Meyer J, Huberth A, Ortega G, Syagailo YV, Jatzke S, Mossner R, et al. A missense mutation in a novel gene encoding a putative cation channel is associated with catatonic schizophrenia in a large pedigree. Mol Psychiatric 2001; 6:302-6. (Pubitemid 32275675)
47. Weiss AP, Goff D, Schacter DL, Ditman T, Freudenreich O, Henderson D, et al. Fronto-hippocampal function during temporal context monitoring in schizophrenia. Biol Psychatric 2006; 60:1268-77. (Pubitemid 44693542)
48. Shenton ME, Dickey CC, Frumin M, McCarley RW. A review of MRI findings in schizophrenia. Schizophr Res 2001; 49:1-52. (Pubitemid 32451739)
49. Burbaeva GS, Savushkina OK, Boksha IS. Creatine Kinase BB in Brain in Schizophrenia. Worl J Biol Psychiatric 2003; 4:177-83.
50. Venables PH. Hippocampal function and schizophrenia. Experimental psychological evidence. Ann NY Acad Sci 1999; 658:111-27.
51. Reddy R, Keshavan MS. Phosphrus magnetic resonance spectroscopy: its utility in examining the membranes hypothesis of schizophrenia. Prostaglandins Leukot E Fat Ac 2003; 69:401-5. (Pubitemid 37464049)
52. Kyosseva SV, Elbein AD, Griffin WS, Mrak RE, Lyon M, Karson CN. Mitogen-activated protein kinases in schizophrenia. Biol Psychiatry 1999; 46:689-96. (Pubitemid 29401865)
53. Yuan J, Yankner BA. Apoptosis in the nervous system. Nature 2000; 407:802-19.
54. Jarskog LF, Selinger ES, Lieberman JA, Gilmore JH. Apoptotic proteins in the temporal cortex in schizophrenia: high Bax/Bcl-2 ratio without caspase-3 activation. Am J Psychiatry 2004; 161:109-15. (Pubitemid 38419315)
55. Mohn AR, Gainetdinov RR, Caron MG, Koller BH. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 1999; 98:427-36. (Pubitemid 29402481)
56. DiCicco-Bloom E, Lord C, Zwaigenbaum L, Courchesne E, Dager SR, Schmitz C, et al. The developmental neurobiology of autism spectrum disorder. J Neurosc 2006; 26:6897-906. (Pubitemid 44309856)
57. Moldin SO, Rubenstein JL, Hyman SE. Can autism speak to neuroscience? J Neurosc 2006; 26:6893-6.
58. Schneider T, Przewlocki R. Behavioral alterations in rats prenatally exposed to valproic acid: animal model of autism. Neuropsychopharmacol 2005; 30:80-9. (Pubitemid 40024402)
59. Niesink RJM, Van Ree JM. Involvement of opioid and dopaminergic systems in isolation-induced pinning and social grooming of young rats. Neuropharmacol 1989; 28:411-8. (Pubitemid 19108802)
60. Hitri A, O'Connor DA, Cohen JM, Keuler DJ, Deutsch SI. Differentiation between MK-801- and apomorphine-induced stereotyped behaviors in mice. Clin Neuropharmacol 1993; 16:220-36. (Pubitemid 23149960)
61. Battisti JJ, Shreffler CB, Uretsky NJ, Wallace LJ. NMDA antagonists block expression of sensitization of amphetamine-and apomorphineinduced stereotypy. Pharmacol Biochem Behav 2000; 67:241-6. (Pubitemid 32000829)
62. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193:265-7.
63. Hughes BP. A method for estimation of serum creatine kinase and its use in comparing creatine kinase and aldolase activity in normal and pathologic sera. Clin Chim 1962; 7:597-604.